292 related articles for article (PubMed ID: 37096862)
21. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis.
Campanaro F; Batticciotto A; Zaffaroni A; Cappelli A; Donadini MP; Squizzato A
Autoimmun Rev; 2021 Oct; 20(10):102902. PubMed ID: 34274542
[TBL] [Abstract][Full Text] [Related]
22. Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis.
Tahir H; Grewal S
Expert Opin Pharmacother; 2022 Mar; 23(4):417-420. PubMed ID: 34787511
[No Abstract] [Full Text] [Related]
23. Comparing available JAK inhibitors for treating patients with psoriasis.
Funk PJ; Perche PO; Singh R; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):281-294. PubMed ID: 35129030
[TBL] [Abstract][Full Text] [Related]
24. Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Navarini L; Currado D; Costa L; Tasso M; Chimenti MS; Caso F
J Exp Pharmacol; 2020; 12():487-502. PubMed ID: 33235521
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Abdulrahim H; Sharlala H; Adebajo AO
Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
[No Abstract] [Full Text] [Related]
26. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature.
Furtunescu AR; Georgescu SR; Tampa M; Matei C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731900
[TBL] [Abstract][Full Text] [Related]
28. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
30. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs for psoriatic arthritis.
Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
[TBL] [Abstract][Full Text] [Related]
32. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Ighani A; Georgakopoulos JR; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
34. TYK2: an emerging therapeutic target in rheumatic disease.
Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
[TBL] [Abstract][Full Text] [Related]
35. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.
D'Urso DF; Chiricozzi A; Pirro F; Calabrese L; Caldarola G; Fossati B; De Simone C; Peris K
G Ital Dermatol Venereol; 2020 Aug; 155(4):411-420. PubMed ID: 32545945
[TBL] [Abstract][Full Text] [Related]
36. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
Braun J; Kiltz U; Baraliakos X
Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
[TBL] [Abstract][Full Text] [Related]
37. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
39. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Kerrigan SA; McInnes IB
Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
[TBL] [Abstract][Full Text] [Related]
40. Psoriatic Arthritis: Newer and Older Therapies.
Chao R; Kavanaugh A
Curr Rheumatol Rep; 2019 Dec; 21(12):75. PubMed ID: 31865449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]